Enliven Therapeutics, Inc. (ELVN) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "ELVN"
      ],
      "issuer_cik": "0001672619",
      "owner_cik": "0001882764",
      "accession_number": "0001882764-26-000009",
      "form_type": "4",
      "filing_date": "2026-10-21",
      "period_of_report": "2026-10-19",
      "issuer_name": "Enliven Therapeutics, Inc.",
      "issuer_trading_symbol": "ELVN",
      "owner_name": "Hohl Benjamin",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "CHIEF FINANCIAL OFFICER",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-19",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 6018,
      "transaction_price_per_share": 38.4755,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 38000,
      "transaction_value": 231545.55899999998,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026."
        },
        {
          "id": "F3",
          "description": "This transaction was executed in multiple trades at prices ranging from $37.785 to $38.765. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."
        },
        {
          "id": "F2",
          "description": "Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU."
        }
      ]
    },
    {
      "tickers": [
        "ELVN"
      ],
      "issuer_cik": "0001672619",
      "owner_cik": "0001701247",
      "accession_number": "0001701247-26-000014",
      "form_type": "4",
      "filing_date": "2026-10-21",
      "period_of_report": "2026-10-19",
      "issuer_name": "Enliven Therapeutics, Inc.",
      "issuer_trading_symbol": "ELVN",
      "owner_name": "Collins Helen Louise",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "CHIEF MEDICAL OFFICER",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-19",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 5000,
      "transaction_price_per_share": 38.4684,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 25000,
      "transaction_value": 192342,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."
        },
        {
          "id": "F3",
          "description": "This transaction was executed in multiple trades at prices ranging from $37.785 to $38.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."
        },
        {
          "id": "F4",
          "description": "These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.